文献速递膀胱癌与上尿路尿路上皮癌

基于Checkmate-901和EV302/Keynote-A39的转移性尿路上皮癌治疗新策略成本效果分析

Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic Urothelial Carcinoma Based on Checkmate-901 and EV302/Keynote-A39.
PubMed 文献 · Eur Urol Oncol · 2024-10-16

该研究从支付方视角构建马尔可夫模型,基于Checkmate-901和EV302/Keynote-A39三期试验数据,分析转移性尿路上皮癌一线治疗的成本效果。在终生 horizon 下,EV+P方案QALYs达2.31,吉西他滨/顺铂+纳武利尤单抗为1.71,标准治疗为1.21;在10万欧元/美元WTP阈值下,德国最优策略为吉西他滨/顺铂+纳武利尤单抗,EV+P需降价46%(美国82%)才具成本效果。

要点

  • EV+P方案QALYs为2.31,吉西他滨/顺铂+纳武利尤单抗为1.71,标准治疗为1.21。
  • EV+P的ICER为€216 140(美国$700 448),吉西他滨/顺铂+纳武利尤单抗为€87 340(美国$281 142)。
  • 在€/$100 000 WTP阈值下,德国最优策略为吉西他滨/顺铂+纳武利尤单抗,EV+P需降价46%(美国82%)才具成本效果。

核心结论

  • EV+P较当前标准治疗QALYs几乎翻倍,但从严格社会经济视角看当前成本可能不合理。
  • 尽管肿瘤学获益较低,吉西他滨/顺铂+纳武利尤单抗因成本效果较好应考虑用于一线治疗,尤其在欧洲。
  • 建立个体风险因素对优化治疗反应和治疗成本至关重要。

研究设计与样本

  • 从支付方视角构建马尔可夫模型,临床数据来自Checkmate-901和EV302/Keynote-A39三期试验。
  • 采用蒙特卡洛模拟从社会经济视角识别德国和美国的最优治疗。
  • 比较各方案在不同支付意愿阈值下的增量成本效果比(ICER)。

主要发现

  • 终生 horizon 下,标准治疗平均成本为€163 424(美国$458 006),吉西他滨/顺铂+纳武利尤单抗为€206 853(美国$597 802),EV+P为€401 170(美国$1 228 455)。
  • 标准治疗QALYs为1.21,吉西他滨/顺铂+纳武利尤单抗为1.71,EV+P为2.31。
  • 吉西他滨/顺铂+纳武利尤单抗ICER为€87 340(美国$281 142),EV+P为€216 140(美国$700 448)。
  • 在€/$100 000 WTP阈值下,德国最优策略为吉西他滨/顺铂+纳武利尤单抗,EV+P需降价46%(美国82%)才具成本效果。

临床怎么用

  • 作者认为,尽管肿瘤学获益较低,吉西他滨/顺铂+纳武利尤单抗因成本效果较好应考虑用于一线治疗,尤其在欧洲。
  • 作者指出,建立个体风险因素对优化治疗反应和治疗成本至关重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Metastatic urothelial carcinoma (mUCa) ranks as the costliest cancer to treat per patient due to frequent interventions and expensive follow-ups. Investigating first-line therapies, combinations such as enfortumab vedotin + pembrolizumab (EV + P) and gemcitabine/cisplatin + nivolumab exhibit significant overall survival benefits compared with the standard treatment (SoC; gemcitabine/cisplatin). Here, we conducted a cost-effectiveness analysis for mUCa. METHODS: We developed a Markov model from a payer perspective, filtering clinical data from the phase 3 Checkmate-901 and EV302/Keynote-A39 trials. Monte Carlo simulation was used to identify the optimal treatment from a socioeconomic perspective in Germany and the USA. Finally, we compared the incremental cost-effectiveness ratio (ICER) of each modality at different willingness-to-pay (WTP) thresholds. KEY FINDINGS AND LIMITATIONS: At a lifetime horizon, SoC, gemcitabine/cisplatin + nivolumab, and EV + P were associated with average costs of €163 424 (USA: $458 006), €206 853 (USA: $597 802), and €401 170 (USA: $1 228 455), and gained quality-adjusted life years (QALYs) of 1.21, 1.71, and 2.31, respectively. The ICERs of the newer strategies were €87 340 (USA: $281 142; gemcitabine/cisplatin + nivolumab) and €216 140 (USA: $700 448; EV + P). At a commonly used WTP threshold of €/$100 000, gemcitabine/cisplatin + nivolumab would be the optimal strategy in Germany, while EV + P would require a price reduction of 46% (USA: 82%) to be cost effective. CONCLUSIONS AND CLINICAL IMPLICATIONS: QALYs nearly double with EV + P compared with the current SoC; yet, current costs may not be justified from a strict socioeconomic perspective. Despite its lower oncological benefit, gemcitabine/cisplatin + nivolumab should be considered for first-line therapy due to favorable cost effectiveness, especially in Europe. Establishing individual risk factors is essential for optimizing therapeutic response and treatment costs in the future. PATIENT SUMMARY: This report presents a cost-effectiveness analysis of emerging treatment options for metastatic urothelial carcinoma. The combination of enfortumab vedotin + pembrolizumab emerged as the most effective treatment; however, it also proved to be the costliest. From a purely socioeconomic standpoint, the combination of gemcitabine/cisplatin and nivolumab represents a cost-effective alternative at least in Germany.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Rieger C, Schlüchtermann J, Lehmann M, et al. Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic Urothelial Carcinoma Based on Checkmate-901 and EV302/Keynote-A39. Eur Urol Oncol. 2024. PMID: 39414420. doi:10.1016/j.euo.2024.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。